ULBP2 (UL16 Binding Protein 2)

Our findings suggest that invasive and bone-metastatic breast cancer cells are more dependent on correct glycosylation and intracellular trafficking for NKG2DL surface expression than non-metastatic breast cancer cells. This difference may have important implications for potential immune evasion mechanisms and for the development of therapeutic strategies targeting bone metastases in breast cancer.

A prognostic model utilizing the RS value was successfully proposed. Meanwhile, we identified PDIA3, PGF, and GRP as novel treatment biomarkers for THCA.

The CD2 receptor is an attractive costimulation target owing to its association with T cell receptor signaling and favorable expression profile...We demonstrate that ULBP2-targeted trispecifics with integrated CD2 costimulation and optimized CD3 affinity are superior to higher-affinity CD3 molecules in in vivo mouse efficacy studies. This integrated CD2 costimulation platform, which we termed EVOLVE, represents a next-generation TCE platform to increase T cell effector function in the tumor microenvironment and has the potential to address unmet patient needs by improving the depth and durability of clinical antitumor T cell responses.

Molecular docking and dynamics simulations revealed valproic acid, cyclosporine, and genistein as potential therapeutic compounds with strong binding affinities to the hub genes...This comprehensive study highlights the potential of ULBP2, INHBB, and STC2 as promising biomarkers for CRC, emphasizing their roles in regulating tumor progression and immune responses. Future studies should focus on targeted therapeutic strategies that utilize these biomarkers to enhance treatment efficacy and patient prognosis.

The combination of an immunomodulatory agent with chemotherapy represents a novel therapeutic strategy for TNBC. TAK-981 not only synergizes with DOX to produce antitumor immun effects but also significantly mitigates DOX-induced cardiotoxicity, offering a promising new direction for improving the efficacy and safety of TNBC treatment.

Advanced PM patients (n = 17) treated with nivolumab plus ipilimumab were prospectively enrolled in the FIL-QI 2021 study. Transcriptomics revealed nine genes differentially regulated according to clinical outcomes, among which ULBP2 emerged as a strong predictor of poor prognosis (LASSO-Cox regression model). Parallel immune and transcriptomic profiling identifies biomarkers predictive of IT benefit in PM.

In conclusion, ULBP2 contributes to GC progression by promoting TGF-β mediated CAF activation, which collectively reinforce the dense stromal microenvironment. Targeting ULBP2 suppresses tumor growth, reduces stromal deposition, and promotes T cell infiltration, thereby enhancing the efficacy of immunotherapy in GC.

  We identified MYL9 and ULBP2 as aging-related markers for the diagnosis of CHD and the prognosis of CRC. In addition, we developed clinical tool models to facilitate the diagnosis of CHD and predict the prognosis of CRC, specifically in the elderly population.

Cellular senescence in SCC exhibits a dual role - initially tumor-suppressive, later promoting invasion and metastasis. Key biomarkers such as CDKN2A and MMPs may serve as therapeutic targets. These findings lay the groundwork for future translational research to improve SCC diagnosis and treatment.

METTL3 modulated the m6A methylation of ULBP2, affecting the oncogenic properties and radioresistance of CC cells.

ULBP2 has potential as a prognostic biomarker and therapeutic target of CRC. These findings provide valuable insights for future studies of tumorigenic mechanisms and clinical applications.

In contrast, anti-CTLA-4 antibody treatment induced marked tumor regression irrespective of ULBP2 expression. These findings suggest that ULBP2-NKG2D signaling may contribute to altered CD8+ T cell phenotypes under T cell-modulatory conditions, potentially impacting the outcome of CD4+CD25+ T cell-targeted therapies and providing insights for optimizing immunotherapeutic strategies.